Blog
RSS FeedPosted by Michael Wonder on 07 May 2025
Omaveloxolone for the treatment of patients with Friedreich’s ataxia
6 May 2025 - NICE is unable to make a recommendation on the use of omaveloxolone (Skyclarys) for the treatment of ...
Posted by Michael Wonder on 02 May 2025
DoH publishes revised agenda for the May 2025 PBAC meeting
2 May 2025 - The agenda for the May 2025 PBAC meeting has been updated. ...
Posted by Michael Wonder on 01 May 2025
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
1 May 2025 - Our final draft guidance recommends linzagolix (Yselty, Theramex) with hormonal add-back therapy for adults of reproductive age ...
Posted by Michael Wonder on 30 Apr 2025
SMC - April 2025 decisions
7 April 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 29 Apr 2025
Institute for Clinical and Economic Review to assess treatments for obesity management
29 April 2025 - Report will be subject of New England CEPAC meeting in November 2025; draft scoping document open ...
Posted by Michael Wonder on 28 Apr 2025
New position statement aims to guide the use of AI methods in health technology assessment
25 April 2025 - Canada’s Drug Agency has published a new position statement on the use of artificial intelligence methods ...
Posted by Michael Wonder on 27 Apr 2025
Dupilumab for the treatment of patients with moderate to severe chronic obstructive pulmonary disease
24 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 27 Apr 2025
Public Summary Documents (first time decisions not to recommend and deferrals) – December 2024 PBAC meeting
24 April 2025 - The Public Summary Documents (first-time decisions not to recommend and deferrals) from the December 2024 PBAC meeting ...
Posted by Michael Wonder on 27 Apr 2025
Recommendations made by the PBAC – March 2025
24 April 2025 - Recommendations made by the PBAC in March 2025 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 26 Apr 2025
CHMP recommends approval of Oczyesa for treatment of acromegaly in the EU
25 April 2025 - Camurus today announced that the EMA's CHMP has adopted a positive opinion for market authorisation of Oczyesa, ...
Posted by Michael Wonder on 25 Apr 2025
Multiple myeloma drug subsidised after treatment costs ballooned
24 April 2025 - It’s one of the few cancers still considered incurable, and those diagnosed with multiple myeloma will likely ...
Posted by Michael Wonder on 22 Apr 2025
EMA publishes agenda for 22-25 April 2025 CHMP meeting
22 April 2025 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 18 Apr 2025
Canada’s Drug Agency announces new 5 year strategic plan
17 April 2025 - Canada’s Drug Agency announces a new 5-year strategic plan, Insight to Impact 2025–2030. ...
Posted by Michael Wonder on 15 Apr 2025
ICER releases draft evidence report on treatment for secondary progressive multiple sclerosis
15 April 2025 - Public comment period now open until 13 May 2025; Requests to make oral comment during public ...
Posted by Michael Wonder on 14 Apr 2025
Thousands of people a year could benefit from new twice a day tablet for advanced breast cancer
11 April 2025 - We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately ...